results
All public Immune-Image resources will be available here, including scientific publications and protocols.
How to obtain the image‑derived blood concentration from 89Zr‑immuno‑PET scans
ABSTRACT Background PET scans using zirconium-89 labelled monoclonal antibodies (89Zr-mAbs), known as 89Zr-immuno-PET, are made to measure uptake in tumour and organ tissue. Uptake is related to the supply of 89Zr-mAbs in the blood. Measuring activity concentrations...
Unveiling the potential of a macrophage-targeted PET tracer: A first-in-human study
Introduction The human immune system contains a complex network of cells and organs, each with their own unique functions. Within this intricate tapestry, macrophages play an indispensable role займ без проверки кредитной истории. These immune cells are involved in a...
Phase I Study of [68Ga]Ga-Anti-CD206-sdAb for PET/CT Assessment of Protumorigenic Macrophage Presence in Solid Tumors (MMR Phase I)
ABSTRACT Purpose Macrophages play an important role throughout the body. Antiinflammatory macrophages expressing the macrophage mannose receptor (MMR, CD206) are involved in disease development, ranging from oncology to atherosclerosis and rheumatoid arthritis....
Validation of simplified uptake measures against dynamic Patlak Ki for quantification of lesional 89Zr-Immuno-PET antibody uptake
ABSTRACT Purpose Positron emission tomography imaging of zirconium-89-labelled monoclonal antibodies (89Zr-Immuno-PET) allows for visualisation and quantification of antibody uptake in tumours in vivo. Patlak linearization provides distribution volume (VT) and nett...
Interrogating Glioma-Associated Microglia and Macrophage Dynamics Under CSF-1R Therapy with Multitracer In Vivo PET/MRI
ABSTRACT Purpose Glioma-associated microglia and macrophages (GAMMs) are key players in creating an immunosuppressive microenvironment. They can be efficiently targeted by inhibiting the colony-stimulating factor 1 receptor (CSF-1R). We applied noninvasive PET/CT and...
Optimal imaging time points considering accuracy and precision of Patlak linearization for 89Zr-immuno-PET: a simulation study
ABSTRACT Purpose Zirconium-89-immuno-positron emission tomography (89Zr-immuno-PET) has enabled visualization of zirconium-89 labelled monoclonal antibody (89Zr-mAb) uptake in organs and tumors in vivo. Patlak linearization of 89Zr-immuno-PET quantification data...
Radiomic Signatures Associated with CD8+ Tumour-Infiltrating Lymphocytes: A Systematic Review and Quality Assessment Study
ABSTRACT Simple Summary: Immune checkpoint inhibitors can be effective drugs to treat cancer. However, only a minority of patients derive benefits. An important determinant of treatment success is the abundance of CD8-expressing tumour-infiltrating lymphocytes (CD8+...
Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica
ABSTRACT Introduction Giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) are two interrelated inflammatory diseases affecting patients above 50 years of age. Patients with GCA suffer from granulomatous inflammation of medium- to large-sized arteries....
Phenotypic, transcriptomic and functional profiling reveal reduced activation thresholds of CD81 T cells in giant cell arteritis
ABSTRACT Objectives Evidence from temporal artery tissue and blood suggests involvement of CD8þ T cells in the pathogenesis of GCA, but their exact role is poorly understood. Therefore, we performed a comprehensive analysis of circulating and lesional CD8þ T...
Imaging and therapeutic targeting of the tumor immune microenvironment with biologics
ABSTRACT Introduction Radioligand theranostics (RT) in oncology use cancer-type specific biomarkers and molecular imaging (MI), including positron emission tomography (PET), single-photon emission computed tomography (SPECT) and planar scintigraphy, for patient...
PROTOCOLS
This section will be updated with Immune-Image protocols.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831514. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
